Open AccessA Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer
Author(s) -
Philip M. Spanheimer,
Amani Bashir,
Allison W. Lorenzen,
Anna Beck,
Junlin Liao,
Ingrid M. Lizarraga,
Lillian M. Erdahl,
Sonia L. Sugg,
Mark Karwal,
Ronald J. Weigel
Publication year - 2021
Publication title -
american journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.896
H-Index - 78
eISSN - 1537-453X
pISSN - 0277-3732
DOI - 10.1097/coc.0000000000000845
Subject(s) - vandetanib , medicine , placebo , breast cancer , immunohistochemistry , tyrosine kinase inhibitor , cancer , oncology , gastroenterology , urology , pathology , tyrosine kinase , receptor , alternative medicine
Preclinical data supports antitumor activity of tyrosine kinase inhibitor vandetanib with Ret as the therapeutic target in breast cancer. We investigated the effect of preoperative vandetanib on markers of proliferation and apoptosis in breast cancer.